卵巢癌类器官模型的研究进展和治疗新策略

doi:10.11904/j.issn.1002-3070.2022.04.010

摘要/Abstract

摘要： 卵巢癌是全球女性生殖系统三大恶性肿瘤之一,严重威胁着女性的生命健康。近年来,研究者不断改进卵巢癌的治疗手段,但是卵巢癌的5年生存率依然并不乐观。随着精准医疗的推行,类器官模型的临床前研究逐渐进入科研工作者的视野。本文旨在介绍卵巢癌相关实验类器官具有高度保持的肿瘤异质性、模拟肿瘤缺氧微环境、模拟肿瘤的发生转移、药物筛选和精准医学、基因编辑系统和模拟疾病。类器官模型库的建立可以改善卵巢癌治疗发展方向。在3D生物打印和类器官的联合下,有望成为未来药物筛选的新途径。

关键词: 卵巢癌, 类器官模型, 肿瘤微环境, 精准医疗, 3D生物打印技术

Abstract: Ovarian cancer is one of three major malignant tumors from female reproductive system in the world,which seriously threatens the life and health of women.In recent years,researchers have continued to improve the treatment of ovarian cancer,but the five-year survival rate of ovarian cancer are still not optimistic.With the implementation of precision medicine,the pre-clinical study of organoid body models has gradually entered the field of scientific researchers'vision.The purpose of this article is to introduce the highly maintained tumor heterogeneity of ovarian cancer related to experimental organoids,simulating tumor hypoxia microenvironment,simulating tumor occurrence and metastasis,drug screening and precision medicine,gene editing system,and stimulating disease.The establishment of organoid body model library can improve the development direction of ovarian cancer treatment.With the combination with 3D bio-printing and organoids,it is expected to become a new approach for drug screening in the future.

Key words: Ovarian cancer, Organoid body model, Tumor microenvironment, Precision medicine, 3D bio-printing technology

中图分类号:

R737.31

孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.

SUN Fusheng, XU Ye, ZHANG Yongjian, LOU Ge. Research progress and new treatment strategies of ovarian cancer organoids[J]. Journal of Practical Oncology, 2022, 36(4): 346-350.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/346

参考文献

1 Liu HD,Xia BR,Jin MZ,et al.Organoid of ovarian cancer:genomic analysis and drug screening[J].Clin Transl Oncol,2020,22(8):1240-1251.
2 Armstrong DK,Alvarez RD,Bakkum-Gamez JN,et al.NCCN guidelines insights:ovarian cancer,version 1.2019[J].J Natl Compr Canc Netw,2019,17(8):896-909.
3 Ma J,Ren S,Ding J,et al.Expression of RRBP1 in epithelial ovarian cancer and its clinical significance[J].Biosci Rep,2019,39(7):20190656.
4 Bowtell DD,Böhm S,Ahmed AA,et al.Rethinking ovarian cancer II:reducing mortality from high-grade serous ovarian cancer[J].Nat Rev Cancer,2015,15(11):668-679.
5 Kuroki L,Guntupalli SR.Treatment of epithelial ovarian cancer[J].BMJ,2020,371:3773.
6 Maenhoudt N,Defraye C,Boretto M,et al.Developing organoids from ovarian cancer as experimental and preclinical models[J].Stem Cell Reports,2020,14(4):717-729.
7 de Witte CJ,Espejo Valle-Inclan J,Hami N,et al.Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses[J].Cell Rep,2020,31(11):107762.
8 Narod SA,Sopik V.Is invasion a necessary step for metastases in breast cancer?[J].Breast Cancer Res Treat,2018,169(1):9-23.
9 Wang R,Zhu Y,Liu X,et al.The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer[J].BMC Cancer,2019,19(1):1091.
10 Narod SA.Personalised medicine and population health:breast and ovarian cancer[J].Hum Genet,2018,137(10):769-778.
11 Jackson SE,Chester JD.Personalised cancer medicine[J].Int J Cancer,2015,137(2):262-266.
12 Lheureux S,Braunstein M,Oza AM.Epithelial ovarian cancer:evolution of management in the era of precision medicine[J].CA Cancer J Clin,2019,69(4):280-304.
13 Nero C,Vizzielli G,Lorusso D,et al.Patient-derived organoids and high grade serous ovarian cancer:from disease modeling to personalized medicine[J].J Exp Clin Cancer Res,2021,40(1):116.
14 Huch M,Koo BK.Modeling mouse and human development using organoid cultures[J].Development,2015,142(18):3113-3125.
15 Huch M,Knoblich JA,Lutolf MP,et al.The hope and the hype of organoid research[J].Development,2017,144(6):938-941.
16 Rossi G,Manfrin A,Lutolf MP.Progress and potential in organoid research[J].Nat Rev Genet,2018,19(11):671-687.
17 Dutta D,Heo I,Clevers H.Disease modeling in stem cell-derived 3D organoid systems[J].Trends Mol Med,2017,23(5):393-410.
18 Nanki Y,Chiyoda T,Hirasawa A,et al.Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing[J].Sci Rep,2020,10(1):12581.
19 Maru Y,Hippo Y.Current status of patient-derived ovarian cancer models[J].Cells,2019,8(5):505.
20 Lõhmussaar K,Boretto M,Clevers H.Human-derived model systems in gynecological cancer research[J].Trends Cancer,2020,6(12):1031-1043.
21 Maru Y,Tanaka N,Itami M,et al.Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors[J].Gynecol Oncol,2019,154(1):189-198.
22 Kopper O,de Witte CJ,Lõhmussaar K,et al.An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity[J].Nat Med,2019,25(5):838-849.
23 Hui L,Chen Y.Tumor microenvironment:sanctuary of the devil[J].Cancer Lett,2015,368(1):7-13.
24 Duan Q,Zhang H,Zheng J,et al.Turning cold into hot:Firing up the tumor microenvironment[J].Trends Cancer,2020,6(7):605-618.
25 Cao K,Zhang G,Zhang X,et al.Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response[J].Oncoimmunology,2021,10(1):1969075.
26 Kast V,Loessner D.3D models for ovarian cancer[J].Adv Exp Med Biol,2021,1330:139-149.
27 Ramamoorthy P,Thomas SM,Kaushik G,et al.Metastatic tumor-in-a-dish,a novel multicellular organoid to study lung colonization and predict therapeutic response[J].Cancer Res,2019,79(7):1681-1695.
28 Hart PC,Bajwa P,Kenny HA.Modeling the early steps of ovarian cancer dissemination in an organotypic culture of the human peritoneal cavity[J].Adv Exp Med Biol,2021,1330:75-94.
29 Zhang S,Dolgalev I,Zhang T,et al.Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma[J].Nat Commun,2019,10(1):5367.
30 Bi J,Newtson AM,Zhang Y,et al.Successful patient-derived organoid culture of gynecologic cancers for disease modeling and drug sensitivity testing[J].Cancers(Basel),2021,13(12):2901.
31 McCorkle JR,Gorski JW,Liu J,et al.Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer[J].PLoS One,2021,16(8):e0254205.
32 Gorski JW,Zhang Z,McCorkle JR,et al.Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance[J].Biomedicines,2021,9(8):1021.
33 Wan C,Keany MP,Dong H,et al.Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer[J].Cancer Res,2021,81(1):158-173.
34 Hill SJ,Decker B,Roberts EA,et al.Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids[J].Cancer Discov,2018,8(11):1404-1421.
35 Zhang S,Iyer S,Ran H,et al.Genetically defined,syngeneic organoid platform for developing combination therapies for ovarian cancer[J].Cancer Discov,2021,11(2):362-383.
36 Jabs J,Zickgraf FM,Park J,et al.Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations[J].Mol Syst Biol,2017,13(11):955.
37 Hoffmann K,Berger H,Kulbe H,et al.Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment[J].EMBO J,2020,39(6):104013.
38 Morgan KM,Riedlinger GM,Rosenfeld J,et al.Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine[J].Front Oncol,2017,7:2.
39 Workman MJ,Mahe MM,Trisno S,et al.Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system[J].Nat Med,2017,23(1):49-59.
40 Curvello R,Alves D,Abud HE,et al.A thermo-responsive collagen-nanocellulose hydrogel for the growth of intestinal organoids[J].Mater Sci Eng C Mater Biol Appl,2021,124:112051.
41 Nagle PW,Plukker JTM,Muijs CT,et al.Patient-derived tumor organoids for prediction of cancer treatment response[J].Semin Cancer Biol,2018,53:258-264.
42 Murphy SV,Atala A.3D bioprinting of tissues and organs[J].Nat Biotechnol,2014,32(8):773-785.
43 Ong LJY,Islam A,DasGupta R,et al.A 3D printed microfluidic perfusion device for multicellular spheroid cultures[J].Biofabrication,2017,9(4):45005.
44 Laronda MM,Rutz AL,Xiao S,et al.A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice[J].Nat Commun,2017,8:15261.
45 Xu F,Celli J,Rizvi I,et al.A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform[J].Biotechnol J,2011,6(2):204-212.

[1]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[2]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[3]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[4]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[5]	牟冠男, 马强. NK细胞极化在子宫内膜癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 534-537.
[6]	隆园辉, 陈雪松. 心理应激对肿瘤微环境中免疫细胞影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 436-440.
[7]	张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.
[8]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[9]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[10]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[11]	邓明新, 张颖. 环状RNA与卵巢癌研究新进展[J]. 实用肿瘤学杂志, 2019, 33(6): 549-552.
[12]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[13]	宋玲, 付琼. 紫云英苷通过上调PHD2抑制缺氧诱导的卵巢癌细胞增殖和侵袭[J]. 实用肿瘤学杂志, 2019, 33(5): 407-414.
[14]	张蓓蕾, 李怡, 吴涛, 姜锋, 赵宏喜, 李艳红. 血根碱通过诱导细胞凋亡抑制卵巢癌肿瘤生长的机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 305-309.
[15]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.